Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes

Figure 5

Ultrathin sections of log phase S. pyogenes DMST 30653 grown in CAMHB-LHB containing (a) control (drug-free); (b) ceftazidime (0.25 μg mL⁻¹); (c) luteolin (64 μg mL⁻¹); (d) quercetin (64 μg mL⁻¹); (e) ceftazidime (0.09 μg mL⁻¹) plus luteolin (12 μg mL⁻¹); (f) ceftazidime (0.09 μg mL⁻¹) plus quercetin (3 μg mL⁻¹). ((a) 195,000x, bar 500 nm; (b) 7,000x, bar 1 μm; (c) 9,900x, bar 500 nm; (d) 15,000x, bar 500 nm; (e) 7,000x, bar 1 μm; (f) 9,900x, bar 500 nm; inset: (a) 34,000x, bar 200 nm; (b) 17,000x, bar 500 nm; (c) 29,000x, bar 200 nm; (d) 15,000x, bar 500 nm; (e) 15,000x, bar 500 nm; (f) 29,000x, bar 200 nm).

(a)

(b)

(c)

(d)

(e)

(f)